BPMC Blueprint Medicines Corporation

96.62

1.81 (1.91%)

22 Nov 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Blueprint Medicines Corporation	NASDAQ:BPMC	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	1.81	1.91%	96.62	80.00	96.62	98.13	92.97	94.98	778,933	01:00:00

Form 144 - Report of proposed sale of securities

07/11/2024 10:24pm

Edgar (US Regulatory)

="/Images/box-unchecked.jpg" alt="Checkbox not checked">500003/01/2023Compensation for Services

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller

Title of Securities Sold

Date of Sale

Amount of Securities Sold

Gross Proceeds

Albers, Jeffrey W.
c/o Blueprint Medicines Corp.
45 Sydney Street
Cambridge � MA � 02139

Common

09/09/2024

19702

1685911.00

144: Remarks and Signature

Remarks

Date of Notice

11/07/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

05/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Aegis J. Frumento as a duly authorized representative of Citigroup Global Markets Inc., as attorney-in-fact for JEFFREY W. ALBERS